BCCA Protocol Summary for First or Second Line Therapy for Invasive Epithelial Ovarian Cancer using Single-Agent CARBOplatin

**Protocol Code**
GOOVCARB

**Tumour Group**
Gynecology

**Contact Physician**
Dr. Ursula Lee

**ELIGIBILITY:**
- patients receiving first line adjuvant treatment for epithelial ovarian carcinoma, primary peritoneal carcinoma, or primary fallopian tube carcinoma who are intolerant of taxanes.
- recurrent, platinum-sensitive, invasive epithelial ovarian carcinoma, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma, or endometrial carcinoma
- continuing clinical or tumour marker improvement after 6 cycles of CARBOplatin-PACLItaxel therapy

**EXCLUSIONS:**
- disease progression while receiving platinum-based chemotherapy
- relative contraindication: disease recurrence less than 6 months after completing platinum-based chemotherapy

**TESTS:**
- **Baseline:** CBC & diff, creatinine, CA 125 tumor marker
- Day 14 and 21 after 1st cycle (and in subsequent cycles if dose-modifications made): CBC & diff; once nadir pattern established, check CBC at that point only
- Before each treatment: CBC & diff, creatinine (if clinically indicated e.g., third space fluid, marked emesis, poor oral intake), any initially elevated tumour marker
- If clinically indicated: liver function tests

**PREMEDICATIONS:**
- ondansetron 8 mg PO 30 minutes pre-CARBOplatin
- dexamethasone 12 mg PO pre-CARBOplatin

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBOplatin</td>
<td>Dose = AUC* x (GFR+25)</td>
<td>IV in 250 mL NS over 30 minutes</td>
</tr>
</tbody>
</table>

*AUC =6; if extensive prior radiation therapy, significant cytopenia with prior therapy, or age greater than 80, use AUC=5.

**Measured GFR** (e.g. nuclear renogram) is preferred whenever feasible, particularly in circumstances of co-morbidity that could affect renal function (third-space fluid accumulations, hypoproteinemia, potentially inadequate fluid intake, etc.). The lab reported GFR (MDRD formula) may be used as an alternative to the Cockcroft-Gault estimate of GFR; the estimated GFR reported by the lab or calculated using the Cockcroft-Gault equation should be capped at 125 mL/min when it is used to calculate the initial CARBOplatin dose. When a nuclear renogram is available, this clearance would take precedence.

BC Cancer Agency Protocol Summary GOOVCARB  Page 1 of 3

Warning: The information contained in these documents are a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is at your own risk and is subject to BC Cancer Agency's terms of use available at www.bccancer.bc.ca/legal.htm
Cockcroft-Gault Formula

\[
GFR = \frac{1.04 \times (140 - \text{age in years}) \times \text{wt (kg)}}{\text{serum creatinine (micromol/L)}}
\]

Note: The same method of estimation should be used throughout the treatment course (i.e. if lab reported GFR was used initially, this should be used for dosing in all subsequent cycles and not the Cockcroft-Gault estimate).
Repeat every 28 days x 6-9 cycles or until disease progression or unacceptable toxicity occurs.

DOSE MODIFICATIONS:
NOTE: Use GFR to determine initial dose, base subsequent doses according to the following:

1. **Hematological**
   On treatment day:

<table>
<thead>
<tr>
<th>ANC (x10^9/L)</th>
<th>Platelets (x10^9/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1 AND greater than or equal to 100</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>less than 1 OR less than 100</td>
<td>delay 1 week or until recovery</td>
<td></td>
</tr>
</tbody>
</table>

   At nadir:

<table>
<thead>
<tr>
<th>ANC (x 10^9/L)</th>
<th>Platelets (x 10^9/L)</th>
<th>CARBOplatin</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1.5 and greater than or equal to 100</td>
<td>120%*</td>
<td></td>
</tr>
<tr>
<td>0.5-1.4 and greater than or equal to 75</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>less than 0.5 and less than 75</td>
<td>80%</td>
<td></td>
</tr>
<tr>
<td>less than 0.5 and greater than or equal to 75</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>greater than or equal to 0.5 and less than 75</td>
<td>80%</td>
<td></td>
</tr>
<tr>
<td>Febrile neutropenia at any time</td>
<td>80%</td>
<td></td>
</tr>
</tbody>
</table>

   *Do not escalate above 120% of Cycle 1 dose.

2. **Renal dysfunction**: Use nuclear renogram or predictive formula to calculate cycle 1 dose, as detailed above. Consider re-calculation of dose if serum creatinine changes ± 20% from baseline.
3. **Neutropenic fever**: If febrile neutropenia occurs at any point during treatment, reduce subsequent CARBOplatin doses to 80%.

PRECAUTIONS:
1. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively.
2. **Hypersensitivity**: Reactions to CARBOplatin may develop in patients who have been extensively pre-treated with this agent. Refer to BCCA Hypersensitivity Guidelines.
Call Dr. Ursula Lee or tumour group delegate at (604) 930-2098 with any problems or questions regarding this treatment program.

Date activated: 01 July 2000

Date last revised: 1 Feb 2014 (revised baseline tumor marker requirements)

References: